Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DX-104 Group B Meningococcal Vaccine in Healthy Adults
NCT07395739Phase 1Recruiting
- Sponsor
- Shanghai Yuguan Biotechnology
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DX-104 in Neisseria meningitidis serogroup B infection (2 arms), sponsored by Shanghai Yuguan Biotechnology. Primary endpoint: Overall safety at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
DX-104
03
Conditions
Neisseria meningitidis serogroup B infection
Beyond the preview
Go deeper on NCT07395739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395739.